抗がん治療のためのLSD1阻害剤:最新の特許レビュー (2022-2025)

Zhoudong Zhang¹, Jiyu Li¹, Zitong Wang¹

¹The Fourth Affiliated Hospital of Soochow University, College of Pharmaceutical Sciences, Suzhou Medical College, Soochow University, Suzhou, China.

Expert opinion on therapeutic patents

|February 20, 2026

まとめ

ライシン特異性デメチラーゼ1 (LSD1) 阻害剤は,がん治療の進歩を図っています. 最近の特許は,LSD1を標的とする多様な小分子を発見し,様々な悪性腫瘍の治療に新たな希望をもたらしています.

科学分野:

エピジェネティクスエピジェネティクス
酵素学酵素学とは
薬用化学薬用化学について

背景:

リシン特異性デメチラーゼ1 (LSD1) は,重要な表遺伝子酵素である.
LSD1はヒストンおよび非ヒストン基板の改変を通じて遺伝子発現を調節する.
LSD1の過剰発現は,がんの発症,進行,および薬剤耐性に関連しています.

研究の目的:

LSD1阻害剤の開発における最近のイノベーションをレビューする.
2022年から2025年の間に特許を取得した小分子LSD1阻害剤を分析する.
新しい阻害剤を分類し,その特性を要約する.

主な方法:

SciFinder,Derwent Innovation,そしてWIPOのデータベースの体系的な文献検索.
2022年から2025年まで発行された特許に焦点を当てます.
構造的および機械的性質に基づく阻害剤の分類.

主要な成果:

新型LSD1阻害剤の識別と分類は,6つの異なるカテゴリーに分類される.
これらの阻害剤の構造的特徴,生物学的データ,設計戦略の要約.
新しく開発された化合物のLSD1相互作用機構の分析.

結論:

最近のLSD1阻害剤は,構造的多様性と新しいメカニズムを示しています.
阻害剤の選択性,安全性,治療用例の最適化における進歩.
将来の研究は,より広範ながん治療の応用のための二重ターゲット戦略と拘束力のあるメカニズムに焦点を当てるべきです.

キーワード:

LSD1 (ライシン特異性デメチラーゼ1)小分子阻害剤小分子阻害剤抗がん療法による抗がん療法エピジェネティック・レグレーション阻害剤の設計戦略

さらに関連する動画

06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.4K

関連する概念動画

02:57

Targeted Cancer Therapies

9.0K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

9.0K

02:34

Inhibition of Cdk Activity

6.1K

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

6.1K

01:26

FDA Approved Drugs: Changes to Approved Drugs

289

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...

289

02:50

Combination Therapies and Personalized Medicine

6.2K

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

6.2K

01:26

Drug Administration and Therapy Phases: Overview

1.5K

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

1.5K

02:56

Treatment Resistant Cancers

3.8K

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...